Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics

We recently discovered mutation signatures reminiscent of BRCA deficiency in the vast majority of a set of primary osteosarcomas (OS). In the current study, we therefore investigated the sensitivity of a panel of OS cell lines to the poly(ADP)-ribose polymerase (PARP) inhibitor talazoparib alone and...

Descripción completa

Detalles Bibliográficos
Autores principales: Engert, Florian, Kovac, Michal, Baumhoer, Daniel, Nathrath, Michaela, Fulda, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564725/
https://www.ncbi.nlm.nih.gov/pubmed/27447864
http://dx.doi.org/10.18632/oncotarget.10720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564725/
https://www.ncbi.nlm.nih.gov/pubmed/27447864
http://dx.doi.org/10.18632/oncotarget.10720

Ejemplares similares